BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
First SpaceX booster for upgraded Starship fails during test in Texas - 22 ways you can conserve the water used to make your food
- 3Flu cases are spiking earlier than usual. What you need to know.
- 4Exploring ways to reduce the impact of space junk on Earth
- 5What you need to know about desalination, a growing source of drinking water
- Israel has clear objectives south of Litani River, but will face difficult choices further north
- Ober Gabelhorn glacier reveals remains of man missing for over three decades
- Watch Blue Origin's huge New Glenn rocket ace its epic landing on a ship at sea (video)
- Audits of Espresso Types: Which Mix Is for You?
- Flash flooding causes highways to close to and from Eilat
- 2026 Golden Globes live updates: Red carpet arrivals will kick off the night; Nikki Glaser set to host
- The best overlooked performances of 2025
- The 15 Most Motivating TED Discusses All Time
- Why boosting production of Venezuela's 'very dense, very sloppy' oil could harm the environment
